Healthcare innovation doesn’t fail because of a lack of science—it fails when governance, execution, and incentives break down. In this episode of Analyzing Healthcare, host Roy Bejarano, CEO & Co-Founder of SCALE Healthcare, sits down with George Syrmalis, Founder & CEO of Bioscience Equity Partners, to unpack how early-stage biotech, medtech, and digital health investments are really evaluated—and why most countries fail to attract global capital. Drawing on decades of experience as a physician, biotech founder, and global investor, George explains why governance, intellectual property, execution quality, and regulatory clarity matter more than geography. The conversation explores early-stage biotech funding, global clinical trial strategy, FDA vs international regulators, Big Pharma’s looming patent cliff, radiopharmaceuticals, AI in drug discovery, and why “innovation without impact” doesn’t get funded. From why the U.S. remains the most attractive biotech market to how Saudi Arabia is rapidly emerging as a future life sciences hub, this episode delivers a rare, operator-level view into how capital actually flows across global healthcare innovation.